Selected publications from the Malmberg lab

You can find the complete publication list on PubMed

2022

  1. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma.
    Cichocki F, Bjordahl R, Goodridge JP, Mahmood S, Gaidarova S, Abujarour R, Davis ZB, Merino A, Tuininga K, Wang H, Kumar A, Groff B, Witty A, Bonello G, Huffman J, Dailey T, Lee TT, Malmberg KJ, Walcheck B, Höpken U, Rehm A, Valamehr B, Miller JS.Nat Commun. 2022 Nov 29;13(1):7341. doi: 10.1038/s41467-022-35127-2.PMID: 36446823 Free PMC article.
     
  2. Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia.
    Haroun-Izquierdo A, Vincenti M, Netskar H, van Ooijen H, Zhang B, Bendzick L, Kanaya M, Momayyezi P, Li S, Wiiger MT, Hoel HJ, Krokeide SZ, Kremer V, Tjonnfjord G, Berggren S, Wikström K, Blomberg P, Alici E, Felices M, Önfelt B, Höglund P, Valamehr B, Ljunggren HG, Björklund A, Hammer Q, Kveberg L, Cichocki F, Miller JS, Malmberg KJ, Sohlberg E. J Immunother Cancer. 2022 Nov;10(11):e005577. doi: 10.1136/jitc-2022-005577.PMID: 36319065 Free PMC article.
     
  3. An optimized platform for efficient siRNA delivery into human NK cells.
    Palacios D, Momayyezi P, Huhn O, Ask EH, Dunst J, Malmberg KJ, Hammer Q.Eur J Immunol. 2022 Jul;52(7):1190-1193. doi: 10.1002/eji.202149710. Epub 2022 Apr 22.PMID: 35416292 Free PMC article.
     
  4. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.
    Hammer Q, Dunst J, Christ W, Picarazzi F, Wendorff M, Momayyezi P, Huhn O, Netskar HK, Maleki KT, García M, Sekine T, Sohlberg E, Azzimato V, Aouadi M; Karolinska COVID-19 Study Group; Severe COVID-19 GWAS Group, Degenhardt F, Franke A, Spallotta F, Mori M, Michaëlsson J, Björkström NK, Rückert T, Romagnani C, Horowitz A, Klingström J, Ljunggren HG, Malmberg KJ. Cell Rep. 2022 Mar 8;38(10):110503. doi: 10.1016/j.celrep.2022.110503. Epub 2022 Feb 21. PMID: 35235832 Free PMC article.

2021

  1. Perturbed NK-cell homeostasis associated with disease severity in chronic neutropenia.
    Sohlberg E, Pfefferle A, Ask EH, Tschan-Plessl A, Jacobs B, Netskar H, Lorenz S, Kanaya M, Kosugi-Kanaya M, Meinke S, Mörtberg A, Höglund P, Sundin M, Carlsson G, Palmblad J, Malmberg KJ. Blood. 2021 Oct 26:blood.2021013233. doi: 10.1182/blood.2021013233. Online ahead of print. PMID: 34699594
     
  2. Advances in immune therapies in hematological malignancies.
    Mazzarella L, Enblad G, Olweus J, Malmberg KJ, Jerkeman M. J Intern Med. 2021 Oct 8. doi: 10.1111/joim.13395. Online ahead of print. PMID: 34624160 Review.
     
  3. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.
    Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, Hancock B, Mahmood S, Abujarour R, Wang H, Tuininga K, Zhang B, Wu CY, Kodal B, Khaw M, Bendzick L, Rogers P, Ge MQ, Bonello G, Meza M, Felices M, Huffman J, Dailey T, Lee TT, Walcheck B, Malmberg KJ, Blazar BR, Bryceson YT, Valamehr B, Miller JS, Cichocki F. Cell Stem Cell. 2021 Sep 9:S1934-5909(21)00350-7. doi: 10.1016/j.stem.2021.08.013. Online ahead of print. PMID: 34525347
     
  4. Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia.
    Chiu E, Felices M, Cichocki F, Davis Z, Wang H, Tuninga K, Vallera DA, Lee T, Bjordahl R, Malmberg KJ, Valamehr B, Miller JS. Mol Ther. 2021 Jun 24:S1525-0016(21)00324-5. doi: 10.1016/j.ymthe.2021.06.018. Online ahead of print. PMID: 34174441
     
  5. Natural killer cell receptors regulate responses of HLA-E-restricted T cells.
    Sullivan LC, Nguyen THO, Harpur CM, Stankovic S, Kanagarajah AR, Koutsakos M, Saunders PM, Cai Z, Gray JA, Widjaja JML, Lin J, Pietra G, Mingari MC, Moretta L, Samir J, Luciani F, Westall GP, Malmberg KJ, Kedzierska K, Brooks AG. Sci Immunol. 2021 Apr 23;6(58):eabe9057. doi: 10.1126/sciimmunol.abe9057.

2020

  1. Deciphering Natural Killer Cell Homeostasis.
    Pfefferle A, Jacobs B, Haroun-Izquierdo A, Kveberg L, Sohlberg E, Malmberg KJ
    Front Immunol 2020 ;11():812
     
  2. TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells.
    Clement D, Goodridge JP, Grimm C, Patel S, Malmberg KJ
    Front Immunol 2020 ;11():753
     
  3. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.
    Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, et al
    Cell Stem Cell 2020 Jun;():
     
  4. Natural killer cell immunotypes related to COVID-19 disease severity.
    Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, et al
    Sci Immunol 2020 08;5(50):

2019

  1. Remodeling of secretory lysosomes during education tunes functional potential in NK cells.
    Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, et al
    Nat Commun 2019 01;10(1):514
     
  2. Intra-lineage Plasticity and Functional Reprogramming Maintain Natural Killer Cell Repertoire Diversity.
    Pfefferle A, Jacobs B, Netskar H, Ask EH, Lorenz S, Clancy T, et al
    Cell Rep 2019 Nov;29(8):2284-2294.e4
     
  3. Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma.
    Enqvist M, Jacobs B, Junlén HR, Schaffer M, Melén CM, Friberg D, et al
    Front Immunol 2019 ;10():2085
     
  4. Induction of the BIM Short Splice Variant Sensitizes Proliferating NK Cells to IL-15 Withdrawal.
    Jacobs B, Pfefferle A, Clement D, Berg-Larsen A, Saetersmoen ML, Lorenz S, et al
    J. Immunol. 2019 02;202(3):736-746
     
  5. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg KJ
    Semin Immunopathol 2019 01;41(1):59-68

2018

  1. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
    Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, et al
    Clin. Cancer Res. 2018 04;24(8):1834-1844
     
  2. Induction of the BIM Short Splice Variant Sensitizes Proliferating NK Cells to IL-15 Withdrawal.
    Jacobs B, Pfefferle A, Clement D, Berg-Larsen A, Saetersmoen ML, Lorenz S, Wiiger MT, Goodridge JP, Malmberg KJ
    J Immunol 2019 Feb;202(3):736-746
     
  3. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, et al
    Cancer Immunol Res 2018 04;6(4):467-480
     
  4. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg KJ
    Semin Immunopathol 2019 01;41(1):59-68
     
  5. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.
    De Santis F, Del Vecchio M, Castagnoli L, De Braud F, Di Cosimo S, Franceschini D, et al
    Cytokine Growth Factor Rev. 2018 12;44():1-10
ES
Content reviewer:
29-11-2023